GemVax & KAEL (CEO: Kim Sang-Jae김상재) completed its phase two clinical trial Friday to move onto to the third trial of “GV1001” for benign prostatic hyperplasia.
According to Health Insurance Review and Assessment Service, benign prostatic hyperplasia, a male disease wherein the prostate around the urethra is abnormally enlarged to block urine discharge, has affected over one million men in 2016 alone.
The study evaluated the safety and efficacy of GV1001 in 161 patients with the disease for 12 weeks and found no significant side-effects. The company will announce complete study results at an international conference later this year, company officials said.
“Based on the result of this study, we will initiate a Phase 3 domestic clinical trial and a global clinical trial as soon as possible,” said Song Hyoung-gon chief of the bio business department. “We are fully committed to developing a treatment for benign prostatic hyperplasia in response to the improvement of health and quality of life of elderly people.”
GemVax & KAEL won patents for GV1001 domestically and in the U.S. in 2016 and 2017, respectively.